Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.
“These impressive results significantly expand our chemical diversity and further strengthen our proprietary position in an exciting area of anti-cancer research.”
"Numerate has demonstrated that its data-driven drug design technology can deliver high quality, novel chemical scaffolds rapidly and cost-effectively," said Troy Wilson, President and Chief Executive Officer of Intellikine. "These impressive results significantly expand our chemical diversity and further strengthen our proprietary position in an exciting area of anti-cancer research."
"It was a privilege to work with Intellikine, which is moving rapidly ahead against a very promising target in cancer," stated Guido Lanza, President and Chief Executive Officer of Numerate. "Our collaboration illustrates the power of our technology platform to add value to a company's pipeline and intellectual property position."
To discover the novel lead compounds, Numerate scientists ran their platform on Amazon's Elastic Compute Cloud (EC2), allowing them to search through hundreds of millions of compounds to identify those with the highest probability of activity against PI3K. Those compounds were then synthesized and their inhibitory activity and other properties verified in the laboratory.
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths